We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Low Total Testosterone Linked to Chronic Disease

By LabMedica International staff writers
Posted on 01 May 2018
A male's total testosterone level may be linked to more than just sexual health and muscle mass preservation. More...
Low amounts of the hormone could also be associated with chronic disease, even among men 40 years of age and younger.

The prevalence of total testosterone (TT) deficiency in men increases with age, and is associated with several deleterious effects to the musculoskeletal system including osteopenia and sarcopenia, as well as with higher rates of all-cause mortality.

Scientists from University of Michigan (Ann Arbor, MI, USA) evaluated the association between total testosterone (TT) deficiency and weakness on multimorbidity in men. Analyses were performed to examine the prevalence of multimorbidity among 2,399 young, middle-aged, and older men, with and without testosterone deficiency. Fasting and non-fasting measures of HDL-cholesterol, triglycerides, and glucose were measured. Non-fasting serum measures of glycated hemoglobin (HbA1c) were included as a diagnostic test for untreated diabetes, which reflects average plasma glucose for the previous ~three-months. TT levels were measured in serum using isotope dilution liquid chromatography tandem mass spectrometry.

The investigators found that multimorbidity was more prevalent among men with testosterone deficiency, compared to normal TT in the entire group (36.6% versus 55.2%). However, differences were only seen within young (testosterone deficiency: 36.4%; normal TT: 13.5%; and older men (testosterone deficiency: 75.0%; normal TT: 61.5%). Low TT and weakness in men were independently associated with multimorbidity at all ages; however, multimorbidity was more prevalent among young and older men with testosterone deficiency. Prevalence of testosterone deficiency was 30.8% for the entire sample, and 22.6%, 35.8%, and 34.6% for young, middle-aged, and older men, respectively.

Mark Peterson, PhD, MS, FACSM, an assistant professor and lead author of the study, said, “We found a large dose-response relationship between the age-specific low total testosterone and moderate total testosterone levels and multimorbidity, even after adjusting for obesity and muscle strength capacity. This means that men should be concerned about declining total testosterone, even if it has not reached a level to warrant a clinical diagnosis of less than 300 ng/dL (10.4 nmol/L).” The study was published on April 12, 2018, in the Journal Scientific Reports.

Related Links:
University of Michigan


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.